medicagoinc | Twitter medicagoinc | Twitter

A Canadian COVID-19 vaccine has been submitted to Health Canada and now it's the first one based in this country to be reviewed here.

Medicago, a biopharmaceutical company headquartered in Quebec City, announced that it started a rolling submission for its plant-derived vaccine which means data can be sent to Health Canada for review once it becomes available instead of all at once.

Editor's Choice: Peel Region Is Calling For A Ban On All Leisure Flights Into Pearson Airport

The phase three trial of 30,000 people will take place in 10 countries starting with Canada, the U.S., the U.K. and Brazil.

Medicago said that this vaccine requires two doses that are administered 21 days apart.

Recently, it was announced that Canada would receive its first shipment of the single-dose Johnson & Johnson vaccine and U.S. President Joe Biden said that he's looking into helping our country by sending surplus vaccines.